genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit.
The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques.
It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 12.4M |
| Three Month Average Volume | 700.5M |
| High Low | |
| Fifty-Two Week High | 0.1184 GBX |
| Fifty-Two Week Low | 0.01208 GBX |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 10 May 2024 |
| Price and Volume | |
| Current Price | 0.02325 GBX |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | -32.45% |
| Thirteen Week Relative Price Change | 55.57% |
| Twenty-Six Week Relative Price Change | -50.41% |
| Fifty-Two Week Relative Price Change | -77.58% |
| Year-to-Date Relative Price Change | -66.92% |
| Price Change | |
| One Day Price Change | -7.92% |
| Thirteen Week Price Change | 57.63% |
| Twenty-Six Week Price Change | -45.93% |
| Five Day Price Change | -15.45% |
| Fifty-Two Week Price Change | -74.73% |
| Year-to-Date Price Change | -64.23% |
| Month-to-Date Price Change | -43.64% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.01648 GBX |
| Book Value Per Share (Most Recent Quarter) | 0.00984 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.01648 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.00984 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.03758 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00047 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0.0022 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.04375 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.04071 GBX |
| Normalized (Last Fiscal Year) | -0.04375 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.04375 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.04071 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.04375 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.04071 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.02101 GBX |
| Cash Per Share (Most Recent Quarter) | 0.00801 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.04159 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -0.03835 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.03117 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -506 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,416 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,087.87% |
| Pretax Margin (Last Fiscal Year) | -10,874.55% |
| Pretax Margin (5 Year) | -910.87% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -9,498.18% |
| Operating Margin (Trailing Twelve Months) | -1,802.57% |
| Operating Margin (5 Year) | -616.60% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -9,363.64% |
| Net Profit Margin (Trailing Twelve Months) | -1,837.50% |
| Net Profit Margin (5 Year) | -797.03% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 1,033.33% |
| Revenue Growth (3 Year) | -50.95% |
| Revenue Change (Trailing Twelve Months) | 300.00% |
| Revenue Per Share Growth | -64.44% |
| Revenue Growth (5 Year) | -62.69% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 16.72% |
| Total Debt (5 Year) | -46.74% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 15.52% |
| EPS Change (Trailing Twelve Months) | -3.09% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,097,000 |
| Net Debt (Last Fiscal Year) | -2,360,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 230 |
| Price to Sales (Trailing Twelve Months) | 46 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -3,857,000 |
| Free Cash Flow (Trailing Twelve Months) | -3,852,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -8 |
| Net Interest Coverage (Trailing Twelve Months) | -7 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 12 |
| Total Debt to Equity (Most Recent Quarter) | 9 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -92.56% |
| Return on Assets (Trailing Twelve Months) | -120.84% |
| Return on Assets (5 Year) | -97.55% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -134.61% |
| Return on Equity (Trailing Twelve Months) | -201.53% |
| Return on Equity (5 Year) | -1,054.04% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -134.27% |
| Return on Investment (Trailing Twelve Months) | -197.86% |
| Return on Investment (5 Year) | -128.51% |